Blood Sugar Control Peptides

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human glucagon-like peptide-1. Used for weight management (Wegovy) and type 2 diabetes (Ozempic). Demonstrates significant effects on appetite regulation and glucose control.

Tirzepatide is a dual GIP/GLP-1 receptor agonist for weight management and type 2 diabetes. Marketed as Mounjaro (diabetes) and Zepbound (weight management). Outperforms semaglutide in head-to-head trials for both glucose control and weight loss.

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks. Currently in Phase 3 development.

Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native GLP-1. FDA-approved as Victoza (diabetes) and Saxenda (weight management). Established efficacy and safety profile with extensive clinical data.

MOTS-c is a 16 amino acid mitochondrial-derived peptide encoded in the 12S rRNA gene. First mitochondrial peptide to enter clinical trials. Emerging evidence for metabolic health, exercise performance, and longevity. Levels decline with age.